{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:42:05Z","timestamp":1791726125610,"version":"4.3.4"},"reference-count":56,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.drudis.2025.104570","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T08:20:59Z","timestamp":1764750059000},"page":"104570","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Biotechnology-based therapies for mitigation of pulmonary fibrosis: an update"],"prefix":"10.1016","volume":"31","author":[{"given":"Satvik","family":"Sangai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhrumi","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0124-1741","authenticated-orcid":false,"given":"Sarika","family":"Wairkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2025.104570_b0005","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/mi.2008.85","article-title":"Pulmonary fibrosis: pathogenesis, etiology and regulation","volume":"2","author":"Wilson","year":"2009","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.drudis.2025.104570_b0010","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/S0140-6736(17)30866-8","article-title":"Idiopathic pulmonary fibrosis","volume":"389","author":"Richeldi","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2025.104570_b0015","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242216481","article-title":"Environmental causes of idiopathic pulmonary fibrosis","volume":"24","author":"Gandhi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104570_b0020","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12931-021-01791-z","article-title":"Global incidence and prevalence of idiopathic pulmonary fibrosis","volume":"22","author":"Maher","year":"2021","journal-title":"Respir Res"},{"key":"10.1016\/j.drudis.2025.104570_b0025","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s40266-016-0366-1","article-title":"Idiopathic pulmonary fibrosis and the elderly: diagnosis and management considerations","volume":"33","author":"Jo","year":"2016","journal-title":"Drugs Aging"},{"key":"10.1016\/j.drudis.2025.104570_b0030","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1164\/rccm.200602-163OC","article-title":"Incidence and prevalence of idiopathic pulmonary fibrosis","volume":"174","author":"Raghu","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.drudis.2025.104570_b0035","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1021\/jm501562a","article-title":"Nintedanib: from discovery to the clinic","volume":"58","author":"Roth","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2025.104570_b0040","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/14656566.2018.1425681","article-title":"Nintedanib for the treatment of idiopathic pulmonary fibrosis","volume":"19","author":"Varone","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.drudis.2025.104570_b0045","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40265-015-0350-9","article-title":"Pirfenidone: a review of its use in idiopathic pulmonary fibrosis","volume":"75","author":"Kim","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2025.104570_b0050","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S2213-2600(18)30502-2","article-title":"Lung transplantation for idiopathic pulmonary fibrosis","volume":"7","author":"George","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.drudis.2025.104570_b0055","unstructured":"Idiopathic pulmonary fibrosis market size, share, growth analysis, by drug type (Pirfenidone and Nintedanib), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Providers), By Region \u2013 Industry Forecast 2024\u20132031. Skyquest. Report ID: SQMIG35H2223, Region: Global, Published Date: February, 2024."},{"key":"10.1016\/j.drudis.2025.104570_b0060","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0272-5231(05)70158-1","article-title":"Pulmonary pathology of acute respiratory distress syndrome","volume":"21","author":"Tomashefski","year":"2000","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.drudis.2025.104570_b0065","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.1172\/JCI139519","article-title":"Contributions of alveolar epithelial cell quality control to pulmonary fibrosis","volume":"130","author":"Katzen","year":"2020","journal-title":"J Clin Investig"},{"key":"10.1016\/j.drudis.2025.104570_b0070","doi-asserted-by":"crossref","DOI":"10.3390\/cells11162489","article-title":"Pathophysiology of pulmonary fibrosis in the context of COVID-19 and implications for treatment: a narrative review","volume":"11","author":"Tran","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.drudis.2025.104570_b0075","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2174\/157340810791233033","article-title":"TGF-\u03b2: titan of lung fibrogenesis","volume":"6","author":"Yue","year":"2010","journal-title":"Curr Enzym Inhib"},{"key":"10.1016\/j.drudis.2025.104570_b0080","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.mam.2018.08.004","article-title":"Developmental pathways in the pathogenesis of lung fibrosis","volume":"65","author":"Chanda","year":"2019","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.drudis.2025.104570_b0085","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-019-1873-x","article-title":"Transforming growth factor (TGF)-\u03b21-induced miR-133a inhibits myofibroblast differentiation and pulmonary fibrosis","volume":"10","author":"Wei","year":"2019","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.drudis.2025.104570_b0090","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0033-2018","article-title":"Matrix abnormalities in pulmonary fibrosis","volume":"27","author":"Upagupta","year":"2018","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.drudis.2025.104570_b0095","series-title":"Biomaterials and Bionanotechnology","first-page":"153","article-title":"Biotechnology-based pharmaceutical products","author":"Deb","year":"2019"},{"key":"10.1016\/j.drudis.2025.104570_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.soncn.2019.08.006","article-title":"An overview of monoclonal antibodies","volume":"35","author":"Bayer","year":"2019","journal-title":"Semin Oncol Nurs"},{"key":"10.1016\/j.drudis.2025.104570_b0105","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/j.1440-1843.2011.01938.x","article-title":"A novel single\u2010chain\u2010Fv antibody against connective tissue growth factor attenuates bleomycin\u2010induced pulmonary fibrosis in mice","volume":"16","author":"Wang","year":"2011","journal-title":"Respirology"},{"key":"10.1016\/j.drudis.2025.104570_b0110","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1080\/14712598.2020.1735346","article-title":"Antibody-based therapies for idiopathic pulmonary fibrosis","volume":"20","author":"Sgalla","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.drudis.2025.104570_b0115","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1183\/09031936.01.00074101","article-title":"Type II alveolar epithelial cells and interstitial fibroblasts express connective tissue growth factor in IPF","volume":"17","author":"Pan","year":"2001","journal-title":"Eur Respir J"},{"key":"10.1016\/j.drudis.2025.104570_b0120","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1183\/13993003.01030-2015","article-title":"FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis","volume":"47","author":"Raghu","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.drudis.2025.104570_b0125","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S2213-2600(19)30262-0","article-title":"Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"8","author":"Richeldi","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.drudis.2025.104570_b0130","article-title":"Pharmacological treatment in idiopathic pulmonary fibrosis: current issues and future perspectives","volume":"19","author":"Sciacca","year":"2024","journal-title":"Multidiscip Respir Med"},{"key":"10.1016\/j.drudis.2025.104570_b0135","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1001\/jama.2024.8693","article-title":"Pamrevlumab for idiopathic pulmonary fibrosis: the ZEPHYRUS-1 randomized clinical trial","volume":"332","author":"Raghu","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.drudis.2025.104570_b0140","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.ajpath.2018.01.009","article-title":"A newly discovered antifibrotic pathway regulated by two fatty acid receptors: GPR40 and GPR84","volume":"188","author":"Gagnon","year":"2018","journal-title":"Am J Pathol"},{"key":"10.1016\/j.drudis.2025.104570_b0145","first-page":"53","article-title":"Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis","author":"Khalil","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.drudis.2025.104570_b0150","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1183\/13993003.01558-2014","article-title":"CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab","volume":"46","author":"Raghu","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.drudis.2025.104570_b0155","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nm1332","article-title":"IL-13 signaling through the IL-13\u03b12 receptor is involved in induction of TGF-\u03b21 production and fibrosis","volume":"12","author":"Fichtner-Feigl","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2025.104570_b0160","article-title":"Therapeutic peptides for treatment of lung diseases: infection, fibrosis, and cancer","volume":"24","author":"Li","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104570_b0165","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.peptides.2012.12.010","article-title":"C-type natriuretic peptide: a new cardiac mediator","volume":"40","author":"Del Ry","year":"2013","journal-title":"Peptides"},{"key":"10.1016\/j.drudis.2025.104570_b0170","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.bbrc.2007.02.085","article-title":"CNP infusion attenuates cardiac dysfunction and inflammation in myocarditis","volume":"356","author":"Obata","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.drudis.2025.104570_b0175","article-title":"C-type natriuretic peptide ameliorates pulmonary fibrosis by acting on lung fibroblasts in mice","volume":"17","author":"Kimura","year":"2016","journal-title":"Respir Res"},{"key":"10.1016\/j.drudis.2025.104570_b0180","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nrd2958","article-title":"Strategies for treating idiopathic pulmonary fibrosis","volume":"9","author":"Du Bois","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2025.104570_b0185","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ijbiomac.2019.04.066","article-title":"Pulmonary delivery of therapeutic proteins based on zwitterionic chitosan-based nanocarriers for treatment on bleomycin-induced pulmonary fibrosis","volume":"133","author":"Zhang","year":"2019","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.drudis.2025.104570_b0190","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.apsb.2016.06.010","article-title":"MicroRNAs in idiopathic pulmonary fibrosis: involvement in pathogenesis and potential use in diagnosis and therapeutics","volume":"6","author":"Li","year":"2016","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.drudis.2025.104570_b0195","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00125-012-2804-x","article-title":"MiR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes","volume":"56","author":"Zhong","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.drudis.2025.104570_b0200","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.omtn.2023.02.031","article-title":"Delivery of anti-microRNA-21 by lung-targeted liposomes for pulmonary fibrosis treatment","volume":"32","author":"Yan","year":"2023","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.drudis.2025.104570_b0205","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12040389","article-title":"Senescence of ipf lung fibroblasts disrupt alveolar epithelial cell proliferation and promote migration in wound healing","volume":"12","author":"Blokland","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drudis.2025.104570_b0210","doi-asserted-by":"crossref","first-page":"466","DOI":"10.2174\/1574888X10666150519092639","article-title":"Stem cell and idiopathic pulmonary fibrosis: mechanisms and treatment","volume":"10","author":"Liu","year":"2015","journal-title":"Curr Stem Cell Res Ther"},{"key":"10.1016\/j.drudis.2025.104570_b0215","doi-asserted-by":"crossref","first-page":"7613","DOI":"10.1021\/acsnano.7b07643","article-title":"Human mesenchymal stem cell derived exosomes alleviate type 2 diabetes mellitus by reversing peripheral insulin resistance and relieving \u03b2-cell destruction","volume":"12","author":"Sun","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.drudis.2025.104570_b0220","article-title":"Adipose-derived mesenchymal stem cell therapy for reverse bleomycin-induced experimental pulmonary fibrosis","volume":"13","author":"Zhao","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2025.104570_b0225","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jconrel.2022.05.039","article-title":"Novel drug delivery systems and disease models for pulmonary fibrosis","volume":"348","author":"Li","year":"2022","journal-title":"J Control Release"},{"key":"10.1016\/j.drudis.2025.104570_b0230","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.5504\/BBEQ.2012.0134","article-title":"Biotechnology in the production of pharmaceutical industry ingredients: amino acids","volume":"27","author":"Stoimenova","year":"2013","journal-title":"Biotechnol Biotechnol Equip"},{"key":"10.1016\/j.drudis.2025.104570_b0235","first-page":"53","article-title":"Stem cell therapy for COVID-19, ARDS and pulmonary fibrosis","author":"Li","year":"2020","journal-title":"Cell Prolif"},{"key":"10.1016\/j.drudis.2025.104570_b0240","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/nrd4363","article-title":"Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies","volume":"13","author":"Mitragotri","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2025.104570_b0245","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.biotechadv.2011.07.004","article-title":"Rational design and optimization of downstream processes of virus particles for biopharmaceutical applications: current advances","volume":"29","author":"Vicente","year":"2011","journal-title":"Biotechnol Adv"},{"key":"10.1016\/j.drudis.2025.104570_b0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics12121184","article-title":"Potential and applications of nanocarriers for efficient delivery of biopharmaceuticals","volume":"12","author":"Zeb","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drudis.2025.104570_b0255","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1080\/14712598.2020.1693541","article-title":"Current challenges in biotherapeutic particles manufacturing","volume":"20","author":"Moleirinho","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.drudis.2025.104570_b0260","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jbiotec.2004.06.007","article-title":"Challenges and solutions for the delivery of biotech drugs \u2013 a review of drug nanocrystal technology and lipid nanoparticles","volume":"113","author":"Muller","year":"2004","journal-title":"J Biotechnol"},{"key":"10.1016\/j.drudis.2025.104570_b0265","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.ejpb.2004.11.006","article-title":"Manufacturing, regulatory and commercial challenges of biopharmaceuticals production: a Finnish perspective","volume":"59","author":"N\u00e4rhi","year":"2005","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.drudis.2025.104570_b0270","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.3390\/pharmaceutics14112533","article-title":"Instability challenges and stabilization strategies of pharmaceutical proteins","volume":"14","author":"Akbarian","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drudis.2025.104570_b0275","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40259-016-0174-5","article-title":"Assessing the immunogenicity of biopharmaceuticals","volume":"30","author":"Pineda","year":"2016","journal-title":"BioDrugs"},{"key":"10.1016\/j.drudis.2025.104570_b0280","series-title":"Pharmaceutical Biotechnology: Drug Discovery and Clinical Applications","first-page":"269","article-title":"Patents in the pharmaceutical biotechnology industry: legal and ethical issues","author":"Resnik","year":"2012"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625002831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625002831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T17:03:00Z","timestamp":1773334980000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644625002831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1359644625002831"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104570","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biotechnology-based therapies for mitigation of pulmonary fibrosis: an update","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104570","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104570"}}